JP2008522972A5 - - Google Patents

Download PDF

Info

Publication number
JP2008522972A5
JP2008522972A5 JP2007544611A JP2007544611A JP2008522972A5 JP 2008522972 A5 JP2008522972 A5 JP 2008522972A5 JP 2007544611 A JP2007544611 A JP 2007544611A JP 2007544611 A JP2007544611 A JP 2007544611A JP 2008522972 A5 JP2008522972 A5 JP 2008522972A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
solvent system
fatty acid
fenofibrate
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007544611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008522972A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/044036 external-priority patent/WO2006062933A2/en
Publication of JP2008522972A publication Critical patent/JP2008522972A/ja
Publication of JP2008522972A5 publication Critical patent/JP2008522972A5/ja
Pending legal-status Critical Current

Links

JP2007544611A 2004-12-06 2005-12-05 脂肪酸エステルを有する安定性フェノフィブラート組成物 Pending JP2008522972A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63312604P 2004-12-06 2004-12-06
PCT/US2005/044036 WO2006062933A2 (en) 2004-12-06 2005-12-05 Stable compositions of fenofibrate with fatty acid esters

Publications (2)

Publication Number Publication Date
JP2008522972A JP2008522972A (ja) 2008-07-03
JP2008522972A5 true JP2008522972A5 (cg-RX-API-DMAC7.html) 2009-01-22

Family

ID=36578470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544611A Pending JP2008522972A (ja) 2004-12-06 2005-12-05 脂肪酸エステルを有する安定性フェノフィブラート組成物

Country Status (12)

Country Link
US (1) US20060188529A1 (cg-RX-API-DMAC7.html)
EP (1) EP1830804A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008522972A (cg-RX-API-DMAC7.html)
KR (1) KR20070098855A (cg-RX-API-DMAC7.html)
CN (1) CN101094647A (cg-RX-API-DMAC7.html)
AU (1) AU2005314197A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518426A2 (cg-RX-API-DMAC7.html)
CA (1) CA2589656A1 (cg-RX-API-DMAC7.html)
EA (1) EA200701228A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007006775A (cg-RX-API-DMAC7.html)
NO (1) NO20073457L (cg-RX-API-DMAC7.html)
WO (1) WO2006062933A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513082A (pt) * 2004-08-06 2008-04-22 Transform Pharmaceuticals Inc formulações de fenofibrato e métodos de tratamento relacionados
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US8524280B2 (en) * 2008-12-15 2013-09-03 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
WO2010085811A2 (en) * 2009-01-26 2010-07-29 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
CA2313024C (en) * 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
EP1140036A2 (en) * 1998-12-18 2001-10-10 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) * 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
MXPA01009839A (es) * 1999-03-31 2002-06-21 Abbott Lab Nuevas formulaciones que comprenden agentes reguladores de lipido.
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability

Similar Documents

Publication Publication Date Title
US10238612B2 (en) Transdermal administration of tamsulosin
JP2007516297A5 (cg-RX-API-DMAC7.html)
IL265774A (en) Diagnosis, prevention and treatment of joint diseases
JP2010077141A5 (cg-RX-API-DMAC7.html)
JP2008524120A5 (cg-RX-API-DMAC7.html)
WO2009050738A3 (en) An orally administerable solid pharmaceutical composition and a process thereof
JP2007509981A5 (cg-RX-API-DMAC7.html)
JP2007506774A5 (cg-RX-API-DMAC7.html)
JPH06305958A (ja) 消炎鎮痛外用貼付剤
JP2008522972A5 (cg-RX-API-DMAC7.html)
JP2011507838A5 (cg-RX-API-DMAC7.html)
CA2742645A1 (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
JP2003508484A5 (cg-RX-API-DMAC7.html)
ES2541141T3 (es) Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
JPH01268633A (ja) L−ドーパの直腸被吸収性形態
JP2011506587A5 (cg-RX-API-DMAC7.html)
JP2009517411A5 (cg-RX-API-DMAC7.html)
HRP20151051T1 (hr) Formulacije src/abl inhibitora
JP2010510194A5 (cg-RX-API-DMAC7.html)
DE602006000819D1 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
HRP20121074T1 (hr) Derivati kinolina i njihovi farmaceutski sastavi
WO2020253833A1 (zh) 口腔透粘膜药物剂型
JP2019214595A (ja) 選ばれた処方物によるガランタミンの向上した脳バイオアベイラビリティおよび親油性プロドラッグの経粘膜投与
WO2015016698A1 (es) Composición farmacéutica con agentes antiinflamatorios y proceso de producción
KR101490708B1 (ko) 록소프로펜 또는 그의 염을 포함하는 경피 흡수용 조성물및 이를 포함하는 경피 투여 첩부제